# Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

> **NCT01270997** · PHASE3 · COMPLETED · sponsor: **Hanwha Chemical** · enrollment: 294 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Etanercept
- **BIOLOGICAL:** Etanercept

## Key facts

- **NCT ID:** NCT01270997
- **Lead sponsor:** Hanwha Chemical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01270997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01270997, "Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01270997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*